NCT07289971

Brief Summary

Researchers want to check how well garlic works inside permanent teeth as a medicament during root canal treatments. Garlic has shown to possess many helpful properties, like reducing inflammation, helping wounds heal, and antimicrobial characteristics. Because conventional medicaments can be expensive or have potential side effects, researchers are actively exploring natural options like garlic. Some lab studies have already shown that garlic gel can kill the microbes inside the teeth. However, no real-life clinical or X-ray studies have been done on using garlic in permanent teeth. This study may help scientists find a much safer and effective new material for dental treatments in the future.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
96

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Jan 2026

Shorter than P25 for phase_3

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 4, 2025

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 17, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

January 20, 2026

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2026

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

January 6, 2026

Status Verified

January 1, 2026

Enrollment Period

1 month

First QC Date

December 4, 2025

Last Update Submit

January 1, 2026

Conditions

Keywords

Intracanal MedicamentAllium SativumCalcium hydroxideRoot canal treatmentPeriapical IndexResolution of Periapical RadiolucencyVisual Analogue ScalePalpationPercussion

Outcome Measures

Primary Outcomes (1)

  • CLINICAL AND RADIOGRAPHIC OUTCOMES

    Clinical success will be based on the absence of the following clinical signs and symptoms: Pain Tenderness to palpation of adjacent soft tissues Tenderness to percussion of involved tooth Radiographic outcomes will be measured in terms of size of Periapical radiolucency. The Periapical status will be assessed using the periapical index (PAI) scoring system by Orstavik. Each tooth will be assigned one of the Periapical index scores for 5 categories within the scale. SCORE POSSIBLE OUTCOME 1. Normal periapical structure 2. Small changes in bone structures 3. Change in bone structure with mineral loss 4. Periodontitis with well-defined radiolucency 5. Severe periodontitis with exacerbating features Periapical radiolucency will be classified as resolved if the Periapical index score is less than or equal to score of 2.

    Time frame for clinical outcomes: Baseline to 2 weeks Time frame for radiographic outcomes: Baseline to 6 months

Study Arms (2)

Experimental group(n=48)

EXPERIMENTAL

Garlic gel will be used as an intracanal medicament

Drug: Allium Sativum as an intracanal medicament

Control group(n=48)

ACTIVE COMPARATOR

Patients will receive informed consent, clinical exam, and preoperative radiographs. After anesthesia and rubber dam isolation, access, cleaning, and shaping of canals will be performed using standard endodontic techniques. Calcium hydroxide (control) will be placed as intracanal medicament, followed by temporary restoration of Cavit and Glass Ionomer cement. After 14 days, if clinical symptoms of pain, tenderness to palpation and percussion resolve, the medicament will be removed, and the canal will be obturated and permanently restored. However, if the patient remains clinically symptomatic, then another dressing of calcium hydroxide will be placed. Finally, clinical outcomes will be recorded after a month and obturation will be delayed until the complete resolution of clinical signs and symptoms. Patients will return after 6 months for clinical and radiographic evaluation, with pre- and postoperative radiographs compared by two endodontists.

Drug: Allium Sativum as an intracanal medicament

Interventions

Patients will receive informed consent, clinical exam, and preoperative radiographs. After anesthesia and rubber dam isolation, access, cleaning, and shaping of canals will be performed using standard endodontic techniques. A sterile paper point will be placed in the canal for pH evaluation, followed by placement of garlic gel with lentulo spiral and temporary restoration of MD Temp and GC Gold Label 2 GIC. Patients will return after 14 days; if symptoms persist, the medicament will be replaced, and the patient will be reviewed again after 14 days and then after one month. Final obturation will only be done once all symptoms have resolved. If the experimental group continues to show symptoms after three dressings, the case will be considered a failure and treated conventionally. When asymptomatic, the medicament will be removed, canals will be irrigated, dried, obturated with gutta-percha and Endoplus sealer. Radiographic outcomes will be evaluated after 6 months by 2 endodontists.

Control group(n=48)Experimental group(n=48)

Eligibility Criteria

Age15 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Patients with the physical status of ASA I and ASA II according to ASA classification.
  • Patients aged from 15-45 years.
  • Mature permanent single-rooted teeth with closed apices.
  • Patients with clinical signs of symptomatic apical periodontitis (pain, tenderness to palpation, and percussion).
  • Patients having radiographic evidence of periapical radiolucency of endodontic origin.
  • Patients who have not taken antibiotics for the past 14 days.
  • Cooperative patients who show good compliance.

You may not qualify if:

  • Patients with physical status of ASA III, IV, and V according to ASA classification.
  • Teeth with a calcified pulp chamber in periapical radiography.
  • Patients who have undergone previous endodontic treatment failure and those with the presence of sinus tract on clinical examination.
  • Teeth having advanced periodontal disease, with the basic periodontal examination (BPE) of 3 and 4.
  • Presence of internal and external resorption of the root as viewed on the periapical radiograph.
  • Presence of vertical root fracture and perforation as viewed on the periapical radiograph

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Faghihi T, Haghgoo R, Taghizade F, Zareiyan M, Mehran M, Ansari G. The clinical and radiographic evaluation of Allium sativum oil (garlic oil) in comparison with mineral trioxide aggregate in primary molar pulpotomy. Dent Res J (Isfahan). 2021 Nov 22;18:100. doi: 10.4103/1735-3327.330881. eCollection 2021.

Related Links

MeSH Terms

Conditions

Periapical Periodontitis

Condition Hierarchy (Ancestors)

Periapical DiseasesJaw DiseasesStomatognathic DiseasesPeriodontal DiseasesMouth DiseasesPeriodontitis

Study Officials

  • Zara Rizwan, Bachelors of Dental Surgery

    University of Health science

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Zara Rizwan, Bachelors of Dental Surgery

CONTACT

Shazia Naz, Masters of Dental Surgery

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Double-blinded parallel arm randomized controlled clinical trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator, MDS Resident

Study Record Dates

First Submitted

December 4, 2025

First Posted

December 17, 2025

Study Start

January 20, 2026

Primary Completion

March 1, 2026

Study Completion

May 1, 2026

Last Updated

January 6, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Sharing IPD in a way that compromises privacy would violate patient consent agreements and breach significant global privacy laws.

Available IPD Datasets

Study Protocol (PMID: 35852013)Access